Jeffrey T. L. Smith net worth and biography

Jeffrey Smith Biography and Net Worth

Executive Vice President and Chief Medical Officer of Zymeworks

Dr. Smith joined Zymeworks in January 2023 as Senior Vice President, Early Stage Development and was promoted to Executive Vice President and Chief Medical Officer in January 2024. He is based at our European hub in Dublin, Ireland. Dr. Smith has held many senior positions within the pharmaceutical industry. Previously, Dr. Smith served as the Managing Director of Alder Biopharmaceuticals Inc. in Dublin, Ireland from March 2017 to October 2019, and as Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc. in Seattle, USA from 2012 to March 2017. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti-IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceuticals Inc. (founded 2004). Dr. Smith received his M.B. B.S. and M.D. from the University of London, UK and is a Fellow of the Royal College of Physicians in London.

What is Jeffrey T. L. Smith's net worth?: The estimated net worth of Jeffrey T. L. Smith is at least $115,214.40 as of January 6th, 2025. Dr. Smith owns 8,890 shares of Zymeworks stock worth more than $115,214 as of May 4th. This net worth estimate does not reflect any other investments that Dr. Smith may own. Learn More about Jeffrey T. L. Smith's net worth.
How do I contact Jeffrey T. L. Smith?: The corporate mailing address for Dr. Smith and other Zymeworks executives is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. Zymeworks can also be reached via phone at (302) 274-8744 and via email at ir@zymeworks.com. Learn More on Jeffrey T. L. Smith's contact information.
Has Jeffrey T. L. Smith been buying or selling shares of Zymeworks?: Jeffrey T. L. Smith has not been actively trading shares of Zymeworks during the last quarter. Most recently, Jeffrey T. L. Smith sold 11,110 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $14.92, for a transaction totalling $165,761.20. Following the completion of the sale, the executive vice president now directly owns 8,890 shares of the company's stock, valued at $132,638.80. Learn More on Jeffrey T. L. Smith's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Kenneth Galbraith (Chair & CEO), Neil Josephson (Insider), Neil Klompas (CFO), Paul Moore (Chief Scientific Officer), Kathryn O'Driscoll (Insider), James Priour (Insider), Jeffrey Smith (Executive Vice President and Chief Medical Officer), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last twelve months, Zymeworks insiders bought shares 20 times. They purchased a total of 1,953,886 shares worth more than $24,522,206.29. During the last twelve months, insiders at the sold shares 3 times. They sold a total of 89,601 shares worth more than $1,336,846.92. The most recent insider tranaction occured on April, 16th when Director Ecor1 Capital, Llc bought 73,953 shares worth more than $825,315.48. Insiders at Zymeworks own 1.9% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 4/16/2025.

Jeffrey T. L. Smith Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/6/2025	Sell	11,110	$14.92	$165,761.20	8,890

Jeffrey T. L. Smith Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Today's Range

Now: $12.96

$12.90

$13.23

50 Day Range

MA: $12.01

$9.44

$13.86

2 Week Range

Now: $12.96

$8.21

$17.70

Volume

309,636 shs

Average Volume

611,498 shs

Market Capitalization

$901.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24